Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: A study of the Hokkaido Hematology Study Group

European Journal of Haematology

Volumn 80, Issue 2, 2008, Pages 160-163

  Sugita, Junichi ^a   Tanaka, Junji ^a   Kurosawa, Mitsutoshi ^b   Fukuhara, Takashi ^c   Hashino, Satoshi ^a   Torimoto, Etsuhiro ^d   Koizumi, Kazuki ^e   Masauji, Nobuo ^f   Nishimura, Susumu ^g   Koda, Kyuhei ^h   Imamura, Masahiro ^a   Kasai, Masaharu ⁱ  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c ASAHIKAWA CITY HOSPITAL   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e SAPPORO CITY GENERAL HOSPITAL   (Japan)

^f Hakodate Municipal Hospital   (Japan)

^g Department of Internal Medicine   (Japan)

^h ASAHIKAWA RED CROSS HOSPITAL   (Japan)

ⁱ SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Mean daily dose

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38049108260     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00982.x     Document Type: Article

References (6)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 344 : 1031 37.
2. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 346 : 645 52.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348 : 994 1004.
4. Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003 9 : 1972 9.
5. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007 25 : 481 96.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 : 2408 17.